Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases

Lignende værker

• Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
  af: Watanabe, Satomi, et al.
  Udgivet: (2021)
• Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
  af: Ortiz, Michael V., et al.
  Udgivet: (2020)
• Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
  af: Andreev-Drakhlin, Alexander, et al.
  Udgivet: (2020)
• SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
  af: Cabanillas, Maria E, et al.
  Udgivet: (2020)
• Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
  af: Dias-Santagata, Dora, et al.
  Udgivet: (2020)